Suven Life Sciences has received third product patent from the Canadian Patent office and sixth from Eurasian Patent office corresponding to the New Chemical Entity (NCE) for treatment of disorders associated with Neurodegenerative diseases. These product patents i.e. 2,507,923 and 12750 are valid until 2013 and 2025 respectively.

The granted claims of the patents include the class of selective 50HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, like Alzheimer's, ADHD, Parkinson, Schizophrenia and Huntington's diseases.

These issued patents are for the same inventions that of the granted patents in various other countries like USA, Europe, etc for their NCE. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various stages of clinical development like at phase-I or phase-II.

Venkat Jasti, CEO of Suven, said, “We are very pleased by the grant of these 2 patents for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated US$ 20 billion market potential globally.”

The company has 12 internally discovered therapeutic drug candidates currently, in pre-clinical stage of development.